ReviewBioengineering & translational medicine2026
Tissue-specific gene delivery approaches.
Review in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung surfactants as a component of lipid nanoparticles for pulmonary mRNA delivery.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
For genetic therapies to have their intended benefit, delivery systems must be designed which reach disease-affected organs with high efficiency. To accomplish this, gene delivery systems must overcome multiple intra- and extracellular barriers to avoid rapid clearance from the body and/or significant accumulation in off-target sites which can lead to undesired side effects (e.g., genotoxicity, immunogenicity). This requires an in-depth knowledge of biomolecular and biophysical interactions at the nano-bio interface to engineer gene vectors which preferentially access specific organs such as the liver, spleen, and brain after systemic administration. In this review, we will discuss the strategies employed to engineer genetic therapies which selectively target organs of interest after systemic administration. We focus on three major classes of nucleic acid delivery systems including adeno-associated viruses, lipid nanoparticles, and polymeric nanoparticles (PNPs) which are all being explored for tissue-specific gene delivery. We will go on to describe how new, highly efficient adeno-associated virus variants as well as engineered lipid and PNPs can be discovered or rationally designed. We also discuss high throughput approaches for screening of these systems to establish important structure-to-function relationships that determine the fate of these gene delivery systems once administered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.